pharmaphorum1d
GSK plans phase 3 for hepatitis B drug bepirovirsen, despite efficacy drop
Hepatitis B affects almost 300 million people worldwide, according to GSK, and while nucleoside/nucleotide analogue (NA) drugs to treat it are available – such as Gilead’s polymerase inhibitor ...
pharmaphorum1d
FDA fast-tracks GSK’s chronic hep B therapy bepirovirsen
GSK’s antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, will get a rapid six-month review from the FDA when it is filed for approval, said the drugmaker this morning. The fast ...
ahajournals.org4d
Myocardial Proteome in Human Heart Failure With Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFpEF) constitutes more than half of all HF but has few effective therapies. Recent human myocardial transcriptomics and metabolomics have identified ...
C&EN4d
Engineering of Conserved Sequence Motif 1 Residues in Halohydrin Dehalogenase HheC Simultaneously Enhances Activity, Stability, and Enantioselectivity
Institut de Química Computacional i Catàlisi (IQCC), Departament de Química, Universitat de Girona, c/Maria Aurèlia Capmany 69, Girona, Catalonia 17003, Spain ...